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ABSTRACT 
 
Infectious mononucleosis (IM) is a constellation of clinical features largely seen in 
adolescence and young adults. It is typified by pharyngitis, prominent cervical 
lymphadenopathy and high fevers. It therefore can be difficult to distinguish the disease 
from the far more common presentation of bacterial tonsillitis (BT). Epstein Barr Virus 
(EBV) causes IM in the majority of cases, and thus a distinguishing feature is an 
associated lymphocytosis, rather than the neutrophilia seen in BT. Along with the 
different aetiology and diagnostic pathways, there are a number of aspects of the disease 
that warrant further research. This thesis aims to investigate the epidemiology, 
diagnosis and management of the disease, as well as providing a review of a number of 
areas of controversy.  
 
IM is associated with a high lymphocyte count and recent publications have sought to 
exploit this as a screening tool. I examined 1000 laboratory results but found that the 
lymphocyte to white cell count alone was not sufficient to act as a screening tool in IM.  
 
IM tends to present as a more severe infection than BT, but there was no literature to 
collaborate what many physicians had noted. The admission rates to a tertiary hospital 
of both diseases were examined over a 20-year period. This allowed us to show that IM 
had a significantly longer hospital stay, providing evidence for the first time of the 
severity of the disease.  
 
As 90% of cases are viral in origin, antibiotics would unsurprisingly not usually have a 
role in the treatment of IM. However, the virally driven pharyngitis can lead to 
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anaerobic overgrowth in the oral cavity contributing to the severity of the symptoms. I 
carried out a randomised controlled trial to demonstrate a significant length of stay 
decrease in those treated with anaerobic antibiotics.  
 
Finally a comprehensive review of multiple controversial topics associated with IM was 
undertaken. I discussed subjects such as the association of IM with Multiple Sclerosis 
(MS), chronic fatigue, splenic rupture, and relationship with malignancies and 
treatment with steroids.  
 
Findings from this thesis may have important clinical implications in the epidemiology, 
diagnosis and management of infectious mononucleosis
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PRESENTATION OF THESIS 
 
This thesis is presented in the format of ‘Thesis by Publication’. Table 1 briefly 
outlines each chapter and the journal in which the chapter has been published.  The 
target audience for each journal and its corresponding current ISI impact factor is also 
indicated. Figures and tables have been listed sequentially throughout the thesis. 
Additional figures, tables and references (that may have been omitted in each published 
chapter due to constraints over publishing space) have been included where appropriate. 
Table 2 outlines a number of supplementary publications on the topic of Infectious 
Mononucleosis, which I have also included. These publications came about directly due 
to the primary publications presented here. Finally, the thesis is referenced in the style 
of Harvard UL. 
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GLOSSARY 
Aetiology- the cause or set of causes, or manner of causation of a disease or condition. 
 
Anaerobic bacteria- are bacteria that do not live or grow when oxygen is present. In 
humans, these bacteria are most commonly found in the gastrointestinal tract. 
 
Blinded study- A study done in such a way that the patients or subjects do not know 
(is blinded as to) what treatment they are receiving to ensure that the results are not 
affected by a placebo effect (the power of suggestion). 
 
Cervical- of the neck 
 
Chronic fatigue syndrome - is a debilitating and complex disorder characterized by 
profound fatigue that is not improved by bed rest and that may be worsened by physical 
or mental activity. 
 
Control group- is a baseline group that receives no treatment or a neutral treatment. 
To assess treatment effects, the experimenter compares results in the treatment group 
to results in the control group 
 
Cytomegalovirus - a kind of herpesvirus that usually produces very mild symptoms in 
an infected person but may cause severe neurological damage in people with weakened 
immune systems and in the newborn 
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Epidemiology- is the study and analysis of the patterns, causes, and effects of health 
and disease conditions in defined populations 
 
Eponymous- relating to, or being the person or thing for whom or which something is 
named 
 
Haematology- is the study of the morphology and physiology of blood 
 
Heterophile antibodies- are antibodies produced against poorly defined antigens. 
These are generally weak antibodies with multispecific activities. 
 
Hypertrophy- Hypertrophy is the increase in the volume of an organ or tissue due to the 
enlargement of its component cell 
 
Hypothesis- a supposition or proposed explanation made on the basis of limited 
evidence as a starting point for further investigation. 
 
Incidence- is a measure of the probability of occurrence of a given medical condition 
in a population within a specified period of time 
 
Incubation period- the period between exposure to an infection and the appearance of 
the first symptoms. 
 
Lymphadenopathy- Enlargement/ disease of the lymph glands  
Lymphocytosis- an increase in the number of lymphocytes (type of white blood cell) 
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Mean- average of a set of values 
 
Median- denoting or relating to a value or quantity lying at the midpoint of a frequency 
distribution of observed values or quantities, such that there is an equal probability of 
falling above or below it. 
 
Monospot – (mononuclear spot test)a form of the heterophile antibody test, is a rapid 
tesat for infectious mononucleosis due to Epstein–Barr virus (EBV). 
 
Multiple Sclerosis- A chronic autoimmune disorder affecting movement, sensation, 
and bodily functions. It is caused by destruction of the myelin insulation covering nerve 
fibers (neurons) in the central nervous system (brain and spinal cord). 
 
Neutrophilia- an elevated level of neutrophils (type of white blood cell) 
 
Nonparametric- statistics not based on parameterized families of probability 
distributions. They include both descriptive and inferential statistics 
 
Peritonsillar abscess (Quinsy): A collection of pus behind the tonsils that pushes one 
of the tonsils toward the uvula 
 
Petechiae- a small red or purple spot caused by bleeding into the skin. 
 
Pharyngitis- Inflammation of the pharynx/sore throat 
  Glossary 
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 xvi 
 
Polymerase chain reaction- is a process used in molecular biology to amplify a single 
copy or a few copies of a piece of DNA across several orders of magnitude, generating 
thousands to millions of copies of a particular DNA sequence. 
 
 Positively skewed- is a measure of the asymmetry of the probability distribution of a 
real-valued random variable about its mean. The skewness value can be positive or 
negative, or even undefined 
 
Primary endpoints-measure outcomes that will answer the primary (or most 
important) question being asked by a trial, such as whether a new treatment is better at 
preventing disease-related death than the standard therapy. 
 
Randomization- A method based on chance alone by which study participants are 
assigned to a treatment group. Randomization minimizes the differences among groups 
by equally distributing people with particular characteristics among all the trial arms. 
 
Sensitivity is the ability of a test to correctly identify those with the disease (true 
positive rate) 
 
Specificity- is the ability of the test to correctly identify those without the disease (true 
negative rate). 
Sequelae- a condition that is the consequence of a previous disease or injury 
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Standard deviation- is a measure that is used to quantify the amount of variation or 
dispersion of a set of data values 
 
Subclinical- relating to or denoting a disease that is not severe enough to present 
definite or readily observable symptoms. 
 
Ubiquitous- Present everywhere. 
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ABBREVIATIONS 
 
• BMJ- British Medical Journal 
• BT- Bacterial tonsillitis  
• CDC- Centre for disease control 
• CONSORT- (CONsolidated Standards of Reporting Trials) 
• CMV- Cytomegalovirus  
• EBV- Epstein Barr Virus  
• HIPE- Hospital In-Patient Enquiry  
• HIV- Human Immunodeficiency Virus 
• IgG- Immunoglobulin G 
• IgM- Immunoglobulin M 
• IM- Infectious Mononucleosis 
• L/WCC- Lymphocyte to White Cell Count ratio 
• NHS- National Health Service 
• SD- Standard deviation 
• WCC- White Cell Count 
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 1 
INTRODUCTION 
 
Infectious Mononucleosis (IM) is a well-recognized disease process, which mainly 
affects teenagers and young adults. A number of controversies remain in the diagnosis, 
treatment and management of potential sequelae of IM. Filatov's disease, Pfeiffer’s 
disease, glandular fever, Turk’s lymphomatosis, Sprunt’s disease, and the kissing 
disease are all synonyms of IM. Each designation gives us an insight into the evolution 
of our understanding of the disease. Nil Flilatov, a prominent 19th century physician, 
considered to be the father of Russian paediatrics, is credited with the first description 
on IM in 1887. He used the name “idiopathic denitis” (Filatov 1887). Just two years 
later a German physician, Emil Pfeiffer, described “Drusenfieber”, or glandular fever, 
independently from Flilatov (Pfeiffer 1889). His description has been portrayed as a 
more comprehensive account of the clinical symptoms and signs that we now recognize 
in those with IM (Evans 1974). Wilhelm Türk was born in 1871 in Silesia in modern 
day Poland, then part of the Austrian empire. He was a renowned haematologist 
credited with many innovations in what was then an emerging field. He gave an 
excellent description of the morphology of the blood and course of disease, which 
would only later would be recognised as IM (Lehndorff 1954). The last of the 
eponymous titles fittingly also gave the disease the name by which we know it today. 
Thomas P. Sprunt and Frank A. Evans published a paper in 1920 clearly describing the 
clinical and haematological picture in a group of students attending Johns Hopkins 
University and for the first time used the term Infectious Mononucleosis (Sprunt and 
Evans 1920).  The Paul-Bunnell test or cold agglutination test was discovered 
serendipitously when Dr Bunnell, working as a research assistant to Dr John Paul, left 
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an incubation tray (investigating a link between serum sickness and rheumatic fever) in 
a fridge overnight. The heterophile antibodies were greatly increased by the cold and 
the serum sample was traced back to a patient with IM (Evans 1974, Paul and Bunnell 
1982). This was further improved upon by using horse red cell (instead of sheep red 
cells), for increased accuracy and speed and became known as the monospot test (Lee 
et al. 1968). The aetiology of the disease remained unclear, even after many young 
medical students were inoculated with the disease(Evans 1950, Niederman and Scott 
1965). The eponymous Epstein Barr virus (EBV) was discovered in 1964 by doctors 
working on the newly diagnosed Burkitt’s disease(Epstein et al. 1964). However it took 
another act of fortune to link the two. A laboratory technician working with Werner and 
Gertrude Henle in 1968 on the EBV virus in Philadelphia became unwell and was 
diagnosed with IM. A comparison of serum samples collected from her before and after 
the onset revealed development of antibodies to EBV (Henle et al. 1968). The 
association was confirmed with a number of prospective studies in the subsequent years 
(Niederman et al. 1970, Sawyer et al. 1971). And the final synonym- Humans are the 
only source of the infection, and transmission occurs primarily through saliva, hence 
its popular label as “the kissing disease” (Guo et al. 2010).  
 
 There is still no evidence based or consensus guidelines for the diagnosis of the 
disease(Ebell 2004). The Hoagland criteria, from a study of 500 patients with IM, are 
the most widely quoted guidelines in the diagnosis of IM. This report states that a 
patient presenting with fever, pharyngitis, and lymphadenopathy, with at least a 50% 
lymphocytosis, a 10% minimum of which are atypical, and confirmed by positive 
serological test can be diagnosed with IM (Hoagland 1975). The heterophile test may 
be falsely negative in up to 25% of adults, or up to 50% of young children(Linderholm 
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et al. 1994), in the first week of symptoms, when antibody levels are below the limit of 
detection of the assay (Hoagland 1975). If strongly suspected, the monospot test may 
be repeated after a week (Pagana et al. 2010). Some recent papers have suggested that 
the a lymphocyte to white cell count (L ⁄WCC) ratio of 0.35 (Wolf et al. 2007) or an 
elevated absolute lymphocyte count (>4x109⁄ L) (Biggs 2011, Biggs et al. 2013) could 
be used as a ‘quick reference tool’ or ‘quickly available alternative test for the detection 
of glandular fever’. The aim of the first chapter of this thesis was to assess the validity 
of these results in a larger matched cohort of patients. The diagnosis of IM was 
investigated using a retrospective analysis of the lymphocyte count of patients who 
have been diagnosed with IM with a positive monospot test. We compared the 
lymphocyte to white cell count ratio of 500 patients with a positive result to 500 patients 
with negative monospot results.  All patients were adults, with paediatric patients 
excluded. The patients were selected from a database from within the department of 
haematology.   
 
EBV is one of the most common viral infections in human beings (Masucci and Ernberg 
1994). In childhood, the disease is usually subclinical, and most of the population will 
have acquired immunity by adolescence (Schuster and Kreth 1992). However infection 
of adolescents or adults results in IM in 30 to 70% of cases and can prove severe 
(Tattevin et al. 2006). EBV infection in childhood is associated with low 
socioeconomic status, poor hygiene and crowding so that improved housing and 
decreasing family sizes may have resulted in a change in the epidemiology of EBV and 
therefore infectious mononucleosis (Crowcroft et al. 1998). Studies have shown that its 
acquisition is delayed in more affluent social classes resulting in increased hospital 
admissions (Morris and Edmunds 2002). Anecdotally IM is a more severe infection 
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than bacterial tonsillitis (BT) requiring a longer stay in hospital, however there is no 
evidence in the literature to support this. The aim of the second part of this thesis was 
to perform an epidemiological review of IM over a 20 years period, in order to compare 
the length of stay in hospital of IM against a cohort of patients diagnosed with BT. The 
Hospital In-Patient Enquiry (HIPE) system was utilised to identify patients. All patients 
that had been coded for emergency admissions for IM were included. Those that have 
been coded for Cytomegalovirus (CMV) or Mononucleosis syndrome were excluded. 
Only patients over 15 were included. We compared this data to patients admitted with 
acute tonsillitis. Those with peritonsillar abscess (quinsy) and post tonsillar bleeds were 
excluded. Incidence and length of were evaluated. Data was analysed by Dr Saunders 
at the Statistical Consulting unit in the University of Limerick. 
 
As predominantly a viral illness, treatment of IM is generally supportive, but a number 
of different treatment modalities have been examined over the years. Antiviral 
treatment with acyclovir has been found to have a positive effect (Andersson et al. 
1986), and to be useful in severe cases of airway compromise (Andersson et al. 1987). 
However their routine use is not currently recommended. A less obvious treatment 
option is that of metronidazole and tinidazole, anaerobic antibacterial agents. EBV 
exerts a transient suppression of immunoglobulin-coating of bacteria harboured on the 
tonsillar surfaces, with consequent abundant bacterial attachment to the epithelial cells 
and massive bacterial colonization on the palatine tonsils and penetration into the 
epithelial cells (Brook and de Leyva 1994, Stenfors et al. 2001). It has been suggested 
that metronidazole may help to hasten recovery in IM by suppression of the oral 
anaerobic flora that might otherwise contribute to the inflammatory process (Brook and 
Deleyva 1996, Brook 2005). A number of small studies were conducted in both 
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metronidazole (Hedstrom et al. 1978, Davidson et al. 1979, Hedstrom 1980, Davidson 
et al. 1982, Dalmau et al. 1990) and tinidazole (Marklund et al. 1984, Marklund et al. 
1986), which demonstrated a positive therapeutic effect of the antibiotics. However 
these studies did not have sufficient numbers to give statistical weight to a 
recommendation of routine metronidazole use, and therefore there is ongoing 
controversy. The aim of the third part of the study is to confirm or reject the hypothesis 
that Metronidazole is of use in the treatment of IM. A randomised controlled trial was 
therefore undertaken in University Hospital Limerick to evaluate the efficacy of the 
antibiotic metronidazole in the treatment of IM. In one arm of the study, patients were 
treated with Benzylpenicillin and Metronidazole and the control arm with 
Benzylpenicillin only, which is the standard of care. Patients given steroids or other 
antibiotics, due to penicillin allergy, were excluded. Daily markers of infection and 
inflammation were observed. Adult (Over 15 years of age) patients were randomised 
on a one is to one basis from throughout 2010-2011. These patients were given 
information on the study and consented to take part in the study. The patients were 
blinded to the medication. We assessed the patients daily with a symptom questionnaire 
and also with daily examinations. The primary outcome was length of stay in the 
hospital.  
 
The fourth and final part of the study was a review of controversial topics in IM. The 
review aims to highlight these areas where there has been recent developments, 
including diagnosis, the association with multiple sclerosis and chronic fatigue, 
treatment of the disease including steroid use, associations with malignancies and at 
what time to return to sport. The review was aimed primarily at General Practitioners 
to assist them in some of the more difficult of contentious topics that could arise when 
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treating patients with IM, particularly in the era of easy access to medical literature via 
the Internet. This review also acts as a summary of the research that was undertaken for 
this thesis it was published after the first three papers, which are all cited in the paper. 
The review also examines possible future areas of research. In a supplementary section, 
four further publications were added that arose as a direct result of the principal papers 
in this Thesis. These included three letters to the Editor and an invited commentary of 
a systematic review and meta-analysis. I felt that these should be included not only to 
further the work that has already been published but also to demonstrate the impact of 
this work. 
 
The overall aim of the project is to further our knowledge of the management of 
infectious mononucleosis. 
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ABSTRACT 
Objective: We investigated the hypothesis that a Lymphocyte/White Cell Count ratio 
should be used as a diagnostic indicator of Infectious Mononucleosis 
 
Design: Retrospective study to compare lymphocyte counts and white blood cell 
counts, against the criterion standard, the mononucleosis spot test. 
 
Setting: Department of Otolaryngology, Mater Misericordiae University Hospital, 
Dublin, Ireland. 
 
Participants: We reviewed 1000 patients who had Monospot assays, 500 positive and 
500 negative. 
 
Main Outcome Measures: The lymphocyte counts and white blood cell ratio was 
calculated and compared with the monospot result to calculate the sensitivity and 
specificity at various ratios.  
 
Results: The lymphocyte counts and white blood cell ratio was significantly different 
in the positive and negative monospot groups  (P<0.05). The mean lymphocyte counts 
and white blood cell ratio in the positive group was 0.49 and the mean L/WCC ratio in 
the monospot negative group was 0.29.A ratio of 0.35 had a specificity of 72.2% and a 
sensitivity of 84% for the detection of glandular fever. A higher ratio will give a greater 
specificity, but a lower sensitivity, and visa versa.  
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Conclusions: The lymphocyte to white cell ratio is not sufficient to diagnose or exclude 
Infectious Mononucleosis. Thus this study does not confirm the conclusions of earlier 
studies. 
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1.1 Introduction 
Infectious mononucleosis was first described as a clinic entity in 1889 when the term 
glandular fever was applied to the triad of pharyngitis, fever, and lymphadenopathy 
(Pfeiffer 1889). The first definition of infectious mononucleosis was made in 1920 
when it was discovered that a number of patients with glandular fever had similar blood 
films. These demonstrated an absolute lymphocytosis, with abnormally abundant 
cytoplasm in mononuclear cells(Sprunt and Evans 1920).  The heterophile antibody test 
became the basis for serologic diagnosis of infectious mononucleosis, when in 1932 
Paul and Bunnell discovered that serum from patients with infectious mononucleosis 
caused sheep erythrocytes to agglutinate (Davidsohn 1937). It was not until 1968 that 
the then newly discovered Epstein-Barr virus was identified as the cause of infectious 
mononucleosis (Henle et al. 1968). However today, there is still no evidence based or 
consensus guidelines for the diagnosis of the disease (Ebell 2004).  
 
Infectious mononucleosis is associated with a high white cell count with a relative 
lymphocytosis and the diagnosis is usually confirmed by a positive monospot test 
(Hoagland 1975). This is the basis for diagnosis in the National Health Service (NHS) 
clinical knowledge summary, a resource for primary care physicians in the UK, on 
infectious mononucleosis (Clinical Knowledge Summaries  2011). It has been 
suggested recently that the lymphocyte to white cell count (L/WCC) ratio could be a 
quickly available alternative test for the detection of glandular fever (Wolf et al. 2007).   
The L/WCC of a series of patients with glandular fever was compared with that of a 
relatively similar number of patients with bacterial tonsillitis and it was concluded that 
a L/WCC ratio higher than 0.35 had a sensitivity of 90% and a specificity of 100% for 
the detection of glandular fever. This indicated a better specificity and sensitivity than 
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the mononucleosis spot test. The aim of our study was to assess the validity of these 
results in a larger matched cohort of patients.  
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1.2 Methods 
1.2.1 Ethical considerations 
 As these data are collected routinely as part of the clinical care of these patients and 
analyzed retrospectively, no patient records or extra patient data were accessed for this 
study. Spreadsheets of data of patients that had had monospot tests were acquired from 
the haematology department and the L/WCC ratio was compared for patients with 
positive and negative results. All patient records were anonymised prior to 
analysis. Therefore no ethical approval was deemed to be required.   
 
1.2.2. Data Gathering and analysis 
1000 monospot tests in patients with tonsillitis both in an outpatient and inpatient 
setting were analysed to compare the L/WCC ratio in 500 positive and 500 negative 
results. All monospot and white cell count differentials were carried out within the 
department of haematology, the Mater Misericordiae University Hospital, Dublin.  
Data was collated using Excel software, and analysed using cross tabulation, 
independent sample t-test and ANOVA tests. 
 
1.2.3 The Monospot test 
The monospot tests were performed with “Clearview IM” detection kits. The Clearview 
Mono test is a qualitative membrane strip based immunoassay for the detection of 
infectious mononucleosis heterophile antibodies in whole blood. In this test procedure, 
bovine erythrocyte extracted antigen is coated on the test line region of the strip. The 
sample reacts with bovine erythrocyte extracted antigen coated particles that have been 
applied to the label pad. This mixture migrates chromatographically along the length of 
the test strip and interacts with the coated bovine erythrocyte extracted antigen. If the 
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sample contains infectious mononucleosis antibodies, a coloured line will appear in the 
test line region indicating a positive result. If the sample does not contain IM 
heterophile antibodies, a coloured line will not appear in this region indicating a 
negative result. To serve as a procedural control, a coloured line will always appear at 
the control line region, indicating that proper volume of specimen has been added and 
membrane wicking has occurred(Clearview IM product information  2010).  
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1.3 Results 
The distribution of the participants by gender and test results is presented in Table 3. 
Overall, there were 42.4% males and 57.6% females in the survey.  
 
Table 3: Patient Demographics 
 
 
We can see from Table 4 that the majority of the patients (more than 70% from each 
group) are outside this range. We see that most of the positive cases are above the 40% 
range and most of the negative cases are below 35% range. So it can be initially inferred 
that the critical L/WCC ratio will lie somewhere in the range 35% to 40%. 
 
Table 4: Patient demographics and L/WCC ratio categories 
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There are two independent groups, one with positive monospot test and the other with 
negative monospot test. In order to compare the mean L/WCC ratio for these two groups 
we will use t-test. The P-P plot can be used to test the normality of the dependent 
variable (if the observed values are close to the expected values, close to linearity, the 
data will be considered normally distributed). The P-P plot of L/WCC ratio for the two 
groups is shown in Figure 1. It is clear from Figure 1 that the data is normally distributed 
for the two groups and we can safely say that the assumptions for using t-test are all 
satisfied.  
 
Figure 1: Normal P-P plot for the L/WCC ratio 
 
 
Table 5 shows descriptive statistical results for L/WCC ratio for the two independent 
groups. We can clearly see the difference in the mean values of the two groups. The t-
test was significant (t=24.797, P=0.00 < 0.05) which shows that there is significant 
difference in L/WCC ratio between the two groups. 
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Table 5: Descriptive statistics for L/WCC ratio 
 
 
For different values of L/WCC ratio we get different values of sensitivity and 
specificity. We see that as the sensitivity increases the specificity decreases and for an 
L/WCC ratio of 0.376 both the sensitivity and specificity are equal (approx. 80%). 
Table 6 gives a detailed analysis of sensitivity and specificity at different L/WCC ratio.  
 
Table 6: Sensitivity and Specificity for different L/WCC ratios 
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The distribution of L/WCC ratio for the two independent groups is shown in Figure 2. 
As mentioned in Table 2b,for a L/WCC ratio of 0.376 the sensitivity and specificity 
equal and approximate to 80%. If we increase or decrease the ratio one of these 
parameters will increase and the other will decrease. If we go for a higher sensitivity 
we can see from the table that we have a lower specificity and vice-versa. Thus we have 
optimized the sensitivity and specificity to calculate the present.  
 
Figure 2: Graphical representation of L/WCC ratio in all patients 
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1.4 Discussion 
1.4.1 Synopsis of key findings 
Our findings demonstrate there is a significant difference between the lymphocyte 
count in patients with infectious mononucleosis and those with negative monospot tests. 
An increased lymphocyte count is associated with a positive monospot results and using 
a L/WCC ratio of 0.35 or greater had a specificity of 72% a sensitivity of 84% for the 
detection of glandular fever. A higher ratio will give a greater specificity, but a lower 
sensitivity, and visa versa. 
 
1.4.2 Strengths and weaknesses of the study  
The foremost strength of this study is the number of monospot results assessed. It is 
comparable to Hoagland’s research from 1975 and has more than 4 times the patients 
in the positive cohort and 5 times the patients in the negative cohort of the more recent 
Wolf study. The Clearview monospot test was used in all cases, as an appropriate 
reference standard, which has been described in the methods section. Verification bias 
is avoided, as all tests were carried out in the same laboratory with the same detection 
kits. The laboratory technicians were essentially blinded, as this was a retrospective 
study. The weaknesses of paper include the fact that the study was carried out with only 
laboratory data without any clinical correlation and included both inpatient and 
outpatient results. There is a possibility therefore that some patients’ results were 
analysed that should have been excluded.  
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1.4.3 Comparisons with other studies 
The objective of this study was to compare our results to a recent paper by Wolf et al, 
however our findings are more in line with an earlier paper by Hoagland (Hoagland 
1975). The Hoagland criteria, from a study of 500 patients with infectious 
mononucleosis, are the most widely quoted guidelines in the diagnosis of infectious 
mononucleosis (Hoagland 1975). This report states that a patient presenting with fever, 
pharyngitis, and lymphadenopathy, with at least a 50% lymphocytosis, a 10% minimum 
of which are atypical and confirmed by positive serological test can be diagnosed with 
infectious mononucleosis (Hoagland 1975, Ebell 2004).  Wolf et al recommended that 
the L/WCC alone could be used to act as a quickly available alternative test for the 
detection of glandular fever (Wolf et al. 2007). They analysed 120 patients with 
glandular fever and 100 with bacterial tonsillitis and reported that a L/WCC ratio higher 
than 0.35 had a sensitivity of 90% and a specificity of 100% for the detection of 
glandular fever. However, 0.35 is marginally above the normal range of Lymphocyte 
to white cell count ratio, which is 0.25-0.33 (Aghenta et al. 2008). Our results with 
much larger numbers showed a sensitivity of 84% and specificity of 72.2% for a ratio 
of 0.35. A higher ratio will give a greater specificity, but a lower sensitivity, and visa 
versa. They also added that the specificity and sensitivity of this test seem to be better 
than the mononucleosis spot itself. For their monospot tests Wolf et al used the 
Monolatex test and they quote low sensitivities and specificities from 63% to 84% and 
84% to 100%. However in an evaluation of 12 Commercial Tests for the detection of 
Epstein-Barr Virus-Specific and Heterophile Antibodies, Bruu et al found, for the 
purpose of detecting heterophile antibodies, that Clearview yielded the best results, with 
sensitivity and a specificity of 95 and 100% respectively (Bruu et al. 2000). They also 
comment that a result may take up to 48 hours, whilst in our institution the monospot 
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test is performed on request, taking no more time than a full blood count and 
differential.  
 
From 1908 a relative lymphocytosis has been recognized as a prerequisite for diagnosis 
and in 1952 Hoagland and Bender recommended that mononucleosis be diagnosed only 
when both characteristic blood smears and heterophile antibodies reactions were 
observed. Furthermore, Hoagland warned that disregarding either the heterophile 
agglutination test or the characteristic blood picture, as prerequisites for diagnosis, 
would perpetuate considerable confusion and error (Hoagland 1960a). 
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1.4.4 Clinical applicability of the study 
Sore throat is a very common presenting complaint to medical practitioners, with over 
40 million visits by adults each year in the United States (Komaroff et al. 1986).   In a 
series of 500 patients with confirmed infectious mononucleosis, at least 98 % presented 
with a sore throat, lymph node enlargement, fever, and tonsillar enlargement and as 
such it can be difficult to distinguish clinically from acute bacterial tonsillitis.   The 
importance in making this distinction lies not only in the different disease progression 
and management, but also with regard to the potential life threatening complications of 
infectious mononucleosis. Anecdotally, the pharyngeal symptoms associated with 
infectious mononucleosis are more severe than with bacterial tonsillitis. This is 
reflected in a longer length of stay in hospital, with IM having near twice the mean in 
patient stay as bacterial tonsillitis (Hospital Episode Statistics  2011). As with bacterial 
tonsillitis, infectious mononucleosis may be associated with peritonsillar abscess, with 
various articles reporting rates of peritonsillar abscess between 0.2 - 23% (Johnsen 
1981, Johnsen et al. 1984, Arkkila et al. 1998, Ebell 2004). Although recurrent 
infectious mononucleosis is not common (Paterson and Pinniger 1955, McSherry 
1982), it is associated with prolonged symptoms, with up to 9% developing chronic 
fatigue syndrome at 6 months(White et al. 1998).  In general infectious mononucleosis 
is treated conservatively with supportive measure but there are a number of studies in 
the literature advocating the use of Metronidazole, with objective improvement in the 
clinical symptoms of tonsillar hypertrophy and a reduction in the duration of pyrexia 
(Davidson et al. 1982, Spelman and Newton-John 1982, Dalmau et al. 1990). Intubation 
and or surgery may be indicated in the acute phase, in patients with upper airway 
obstruction whose condition does not improve after intensive medical management. 
Those patients with severe infectious mononucleosis requiring steroid treatment were 
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also found to be more likely to require a tonsillectomy subsequently for recurrent 
bacterial tonsillitis (Stevenson et al. 1992, Chan and Dawes 2001).  Life threatening 
complications can occur in up to 5% of cases, and include upper airway obstruction, 
splenic rupture, neurological complications, pericarditis and myocarditis (Daniels et al. 
1979). 
 
The study by Wolf et al recommended that the L/WCC should be used as a screening 
tool and our results concur that a high L/WCC is a good indicator of infectious 
mononucleosis. However, if we were to follow the suggested algorithm and not perform 
a monospot test on patients with a L/WCC less than 0.35, one in seven of the patients 
with infectious mononucleosis would be missed leading to mismanagement and 
potentially increase morbidity from the disease.  We therefore propose that the L/WCC 
ratio should be used in conjunction with the Hoagland criteria. 
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ABSTRACT 
Introduction 
Anecdotally Infectious Mononucleosis is a more severe infection than Bacterial 
Tonsillitis, requiring a longer hospital stay. There is little in the literature comparing 
the epidemiology of the two. The aim of our study was to compare the epidemiology 
of Bacterial tonsillitis and Infectious Mononucleosis and in particular the difference in 
length of in hospital stay between the two. 
 
Methodology 
The hospital in-patient enquiry system was used to analyse patients admitted with 
Infectious Mononucleosis and Bacterial Tonsillitis, between 1990 and 2009 inclusive.  
 
Results 
There were a total of 3435 cases over the 20 years, 3064 were Bacterial Tonsillitis and 
371 were infectious mononucleosis. The mean length of stay for Bacterial Tonsillitis 
was 3.22 days and Infectious Mononucleosis was 4.37. The median length of stay’s 
were tested using the Mann-Whitney U nonparametric test and were found to be 
significantly different  (p<0.001) 
 
Conclusion 
Infectious mononucleosis requires a significantly longer stay in hospital than Bacterial 
Tonsillitis. 
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2.1 Introduction 
Epstein-Barr virus (EBV) is one of the most common viral infections in human 
(Masucci and Ernberg 1994). In childhood, the disease is usually subclinical and early 
infection is associated with poor hygiene and over crowding.  Most of the population 
in the lower socioeconomic groups will have acquired immunity by adolescence 
(Schuster and Kreth 1992). 
 
EBV infection of adolescents or adults results in Infectious Mononucleosis in up to 
70% of cases and can prove severe (Tattevin et al. 2006).  Improved housing and 
decreasing family sizes may have resulted in a change in the epidemiology of EBV and 
therefore infectious mononucleosis. Acquisition of EBV is often delayed in more 
affluent social classes resulting in increased hospital admission (Crowcroft et al. 1998). 
A recent increased rate of hospital admission has been documented (Morris and 
Edmunds 2002, Tattevin et al. 2006).  
 
Anecdotally Infectious Mononucleosis is reported to be a more severe infection than 
bacterial tonsillitis (BT) thus requiring a longer stay in hospital, however there is no 
evidence in the literature to support this. The aim of our study was to compare the 
duration of hospital admission for patients admitted with severe bacterial tonsillitis and 
Infectious Mononucleosis. 
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2.1 Methods 
A 20-year retrospective analysis was undertaken, between the years 1990-2009 
inclusive. We compared hospital admissions for BT and IM in the University Hospital, 
Limerick, Ireland. Epidemiological information was acquired through the Hospital in 
Patient Enquiry System. Those coded for emergency admission with infectious 
mononucleosis and bacterial tonsillitis under the otolaryngology department were 
included. The indications for admission were inability to take oral antibiotics, airway 
management, and requirements for intravenous rehydration or lack of response to oral 
therapy. Bacterial Tonsillitis is often diagnosed clinically, and in accordance to the 
Hoagland criteria if Infectious Mononucleosis is suspected, a patient with fever, 
pharyngitis, lymphadenopathy, and lymphocytosis, can have the diagnosis confirmed 
by positive serological test (Hoagland 1975, Lennon et al. 2010). Those under 15 were 
excluded as they were primarily treated by the paediatric service.  This data was 
compared to patients admitted with acute tonsillitis. Those with peritonsillar abscesses 
were excluded. Incidence and length of stay were evaluated, was age and sex of the 
patients. Data was analysed with Mann-Whitney U nonparametric, Fishers exact and 
chi-squared, and nonparametric Kruskal-Wallis tests by the Statistical Consulting Unit 
at the Graduate Entry Medical School, University of Limerick.  
 
Incidence rates were calculated by using population data by county, provided by the 
Central Statics Office, Ireland. These were generated from census data over the 20-year 
period (Central Statistics Office, Ireland 2011). Counties in the Mid-Western area that 
are covered by the University Hospital include Limerick, Clare and North Tipperary. 
2.3 Results  
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There were a total of 3435 cases over the 20 years, 3064 were Bacterial Tonsillitis and 
371 were Infectious Mononucleosis. The incidence rates are for the total mid-west 
population. There was 1.6 cases of Infectious Mononucleosis per 100,000 in 1990 
requiring hospital admission and 5.5/100,000 in 2009. The highest incidence of 
Infectious Mononucleosis occurred in 2000 with 7.8/100.000. There were 27/100,000 
cases of Bacterial Tonsillitis in 1990 and 45/100000 in 2009. The peak year for 
Bacterial Tonsillitis was 2001 with 64/100,000 (Fig 3). 
 
 
Figure 3: Prevalence rates of Bacterial Tonsillitis and Infectious Mononucleosis 1990-2009 
 
The mean age for Bacterial Tonsillitis was 25.7 yrs, median age 22 yrs, SD 11.06 and 
range 15-87 yrs. The mean age for Infectious Mononucleosis was 20.0 yrs, median age 
18 yrs, SD 6.32 and range 15-70 yrs. The distributions of age for both conditions were 
positively skewed. The median ages were tested between the conditions using the 
Mann-Whitney U nonparametric test and were found to be significantly different  
(p<0.001), the average age of those with Infectious Mononucleosis were significantly 
lower than those with Bacterial Tonsillitis (Fig 4, Fig 5).  
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Figure 4: Age distribution of patients diagnosed with BT 
 
 
Figure 5: Age distribution of patients diagnosed with IM 
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Numbers of each gender per disease were summarised and tested for difference between 
conditions and this was not significant (p=0.098) using Fishers exact test. However this 
is almost significant and it should be noted that there was a larger percentage of females 
in the bacterial tonsillitis group and a larger percentage of males in the Infectious 
Mononucleosis group.  
 
Length of stay was also tested between diseases and the distribution was positively 
skewed again. The mean length of stay for Bacterial Tonsillitis was 3.22, median 3, SD 
1.54 and range 1-19. The mean length of stay for Infectious Mononucleosis was 4.37, 
median 4, SD 2.37 and range 1-15.  
 
Figure 6: Length of stay- BT 
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Figure 7: Length of stay- IM 
 
The median length of stay were tested between the conditions using the Mann-Whitney 
U nonparametric test and were found to be significantly different  (p<0.001) with the 
median length of stay of those with Bacterial Tonsillitis being significantly lower than 
those with Infectious Mononucleosis, (Fig 6, Fig7, Fig8). 
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Figure 8: Box plot comparing LOS of IM and BT with outliers 
 
Mean length of stay was significantly different between ages (p<0.001). Means tended 
to increase with age. Again mean length of stay tended to be higher for those with 
Infectious Mononucleosis than Bacterial Tonsillitis (Fig 9) 
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Figure 9: Length of stay per age by IM and BT 
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2.4 Discussion 
The incidence of Infectious Mononucleosis did increase during the 20-year period from 
1.6 to 5.5/100,000. The incidence peaked in the late 1990s and early 2000s. The mean 
incidence was 5.4/100,000. Fig 10. This compares to an admission rate of 4.2/100,000 
in England between 1998 and 2005 (Ramagopalan et al. 2011). A rise in incidence of 
hospital admissions for Infectious Mononucleosis has also been noted in England and 
Wales from 2.6-4.8/100,000 from 1989-1998, (Morris and Edmunds 2002).  
 
 
Figure 10: IM rate per 100,000 population (current study versus quoted rate in England) 
 
 
A decrease in GP visits, especially in the young, along with the increase in hospital 
admission led Morris et al to conclude that the most likely explanation for the patterns 
they observed would be that falling childhood infection rates have resulted in an 
increase in the number of teenagers who are susceptible to a severe primary infection. 
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EBV infection in childhood is associated with low socioeconomic status (Crowcroft et 
al. 1998), so the economic boom Ireland experienced from the mid 1990s to the late 
2000s may have resulted in a change in the epidemiology of EBV and therefore 
infectious mononucleosis (FitzGerarld 1999, GDP per capita in Purchasing Power 
Standards (PPS) (EU-27 = 100)  2011). However it is likely that both our report and 
that of Morris et al have too short a lag phase to predict a continuing trend in the rise in 
incidence of Infectious Mononucleosis.  
 
We found a significantly younger age for those admitted with Infectious Mononucleosis 
than Bacterial Tonsillitis. In developed countries the highest incidence is in the 15-to-
25 year-old age group (Evans and Kaslow 1997). Therefore a mean age of 20 for 
Infectious Mononucleosis is in line with other epidemiological reports. A mean age of 
18.3 was found in Wisconsin in 1961 (Evans 1961),  and 19.3 years in Norway in 1978 
(Munoz et al. 1978, Evans and Kaslow 1997). A slightly younger mean age was found 
for females than males in one paper (female 17·0 years, males 19·5 years) which was 
explained in that paper by earlier maturity of females(Odegaard 1967). Infectious 
Mononucleosis is more likely to occur earlier in developing countries(Carvalho et al. 
1973), whilst Infectious Mononucleosis is rare in the elderly(Axelrod and Finestone 
1990). A review of the literature between 1968-1987 found just 29 cases in patients 
over 60 (Schmader et al. 1989). There was a single patient over 60 with Infectious 
Mononucleosis in our cohort of 371.The mean age of patients admitted with Bacterial 
Tonsillitis was 25.7 years. Although children from the age of 5-15 years old are most 
likely to be diagnosed with Bacterial Tonsillitis (Clinical Knowledge Summaries  
2011), when an adult is admitted they tend to be older than patients with Infectious 
Mononucleosis. Studies with mean ages of 27.3 years (Bhattacharyya and Kepnes 
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2002) and 27.7 years (Gallegos et al. 1995) have been published whilst a significantly 
lower age of 23 for Infectious Mononucleosis compared with 27 was also noted in a 
study (Wolf et al. 2007).  
 
Although not significant, we noted larger percentage of females in the Bacterial 
Tonsillitis group and a larger percentage of males in the Infectious Mononucleosis 
group. Another recent paper found a larger percentage of females in the Infectious 
Mononucleosis group in their study. This too was not significant (Mahmud et al. 2011). 
Overall Infectious Mononucleosis seems to occur equally in both sexes (Evans and 
Kaslow 1997).  
 
The average length of stay was found to be significantly longer for IM (mean 4.37, 
median 4 days) than BT (mean 3.22, median 3 days). For Infectious Mononucleosis this 
again is comparative to the literature with a study from 2005 having a mean length of 
stay of 4.6 days (Thompson et al. 2005). However in one paper the average length of 
stay for Infectious Mononucleosis was more than double of what we found at 9.2 days 
in Hungary (Almasi et al. 2001). Raw data from the NHS shows a mean length of stay 
of 2.2 days for Infectious Mononucleosis and 1 day for acute tonsillitis in 2009-10 
(Hospital Episode Statistics  2011). This is not likely to represent severe Bacterial 
Tonsillitis, however there is little in the literature regarding length of stay for Bacterial 
Tonsillitis. One report from Maine in 1975 gave a mean length of stay at 3.28 days 
(Wennberg et al. 1975). Infectious Mononucleosis in patients over 40 often present 
with atypical signs and symptoms and can therefore have a longer hospital stay (Halevy 
and Ash 1988).  
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A longer length of stay may be due to fact that Infectious Mononucleosis is generally 
treated supportively, as it is a viral infection. Acyclovir has been shown to be ineffective 
in treating the symptoms of Infectious Mononucleosis (Torre and Tambini 1999) and 
although steroids have only been shown to of benefit in cases of upper airway 
obstruction they do not decrease the length of stay (Thompson et al. 2005). As a 
bacterial disease, tonsillitis is most commonly limited to the pharynx, whilst Infectious 
Mononucleosis is a systemic disease. Tonsils have shown to be more susceptible to 
bacterial infection with Infectious Mononucleosis (Stenfors et al. 2001, Stenfors et al. 
2003) in particular anaerobic bacteria (Brook 2005). This has led to some treating 
Infectious Mononucleosis with Metronidazole, and several studies have demonstrated 
faster acute and long-term recovery in Infectious Mononucleosis with metronidazole 
(Hedstrom et al. 1978, Hedstrom 1980, Davidson et al. 1982, Spelman and Newton-
John 1982, Dalmau et al. 1990). Infectious Mononucleosis can also be difficult to 
diagnose(Lennon et al. 2010), which may lead to a delay in treatment and is also 
associated with more severe complications than Bacterial Tonsillitis. 
 
Physicians and hospital managers are increasingly under pressure to monitor and 
improve economic performance. Length of stay data is increasingly used to monitor 
economic performance, (Rapoport et al. 2003). Increased length of stay is associated 
with higher cost per patient(Stock and McDermott 2011). Expected length of stay is 
used health indicator of efficiency in many countries (Information 2005).  In this 
environment therefore it important to note the significant difference we found between 
the length of stay of Infectious Mononucleosis and Bacterial Tonsillitis. 
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The strengths of the paper lie in the fact that it a 20 year study from a single institution 
comparing large numbers of commonly treated diseases. The data is from a single 
Hospital in Patient Enquiry System and the Consultant Biostatistician at a University 
Medical School carried out the statistical analysis. The weaknesses include that 
readmission were not identified in the study. Also the fact that treatment of both 
Infectious Mononucleosis and Bacterial Tonsillitis would have been carried out by a 
large number of different physicians over the 20-year period and allow that different 
treatment regimes may have been in place throughout the years. Therefore we must rely 
on the accuracy of the Hospital in Patient Enquiry System.  
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2.5 Conclusions 
This is a large epidemiological study with a long time line. There are not many such 
studies on Infectious Mononucleosis in the recent literature and none comparing 
Infectious Mononucleosis to Bacterial Tonsillitis. Our results concur with many of the 
studies on the incidence, age and sex distribution of Infectious Mononucleosis and 
Bacterial Tonsillitis and a trend to an increasing incidence of Infectious Mononucleosis 
has also been noted. We have however for the first time demonstrated that Infectious 
Mononucleosis is indeed a more severe infection, with a significantly longer stay in 
hospital. 
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2.6 Summary 
• Infectious Mononucleosis is a differential for Bacterial Tonsillitis 
• Anecdotally Infectious Mononucleosis is a more severe infection than Bacterial 
Tonsillitis 
• There is a trand of increasing incidence of Infectious Mononucleosis 
• Severe Infectious Mononucleosis occurs in a younger age than Bacterial 
Tonsillitis 
• Infectious Mononucleosis requires a longer stay in hospital 
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ABSTRACT 
Metronidazole may be of use in the treatment of infectious mononucleosis (IM). Our 
aim is to show that metronidazole shortens hospital stay for patients with severe IM. A 
single-centre randomized controlled trial was undertaken in patients admitted with 
severe IM, who were with a similar group treated by the standard care. Patients were 
blinded to which treatment arm they were in. Forty-two of these patients were enrolled 
in the trial. The primary endpoint was the difference in length of stay. This was 
significantly less in the metronidazole group (3.67 days v 4.67) (p 0.032). This study 
demonstrates that metronidazole has a role to play in severe infectious mononucleosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3                                                RCT: Metronidazole in Infectious 
Mononucleosis 
 42 
3.1 Introduction 
Epstein Barr Virus (EBV) is one of the most common viral infections in human beings 
(Masucci and Ernberg 1994).  In childhood, the disease is usually subclinical, and most 
of the population will have acquired immunity by adolescence (Schuster and Kreth 
1992). However infection of adolescents or adults results in Infectious Mononucleosis 
(IM) in 30 to 70% of cases and can prove severe (Tattevin et al. 2006), with theses 
patients having a significantly longer hospital stay than those admitted with a bacterial 
tonsillitis. Metronidazole is an antibiotic medication used primarily in infections caused 
by anaerobic bacteria and protozoa. There is some evidence that this antibiotic may also 
be efficacious in the treatment of IM (Hedstrom et al. 1978). A possible mechanism of 
its action in infectious mononucleosis is through suppression of the oral anaerobic flora 
(Brook and de Leyva 1994, Kopec et al. 1997, Brook 2005). Previous studies have 
demonstrated a more rapid regression of symptoms in those taking metronidazole 
(Hedstrom et al. 1978, Davidson et al. 1979, Hedstrom 1980, Davidson et al. 1982, 
Dalmau et al. 1990), however a single study showed no difference in those taking 
metronidazole (Spelman and Newton-John 1982). Therefore there is ongoing 
controversy and the treatment of IM with metronidazole has not gained widespread 
acceptance.  The hypothesis of our study is that metronidazole does shorten hospital 
stay and our primary objective is to demonstrate this by undertaking a randomized 
controlled trial in adults admitted with severe IM and compare them to a similar group 
treated by the standard of care.  
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3.2 Methods 
3.2.1 Trial design, inclusion and exclusion criteria 
The trial was a single centre prospective randomized controlled trial. Each patient was 
randomized to the control or intervention arm of the trial on a one to one basis. Both 
males and female patients diagnosed with IM were eligible for inclusion in the trial if 
they were 15 or over and admitted under the care of the Otolaryngology team at the 
University Hospital, Limerick, a tertiary referral centre for the mid-western region of 
Ireland. Patients were diagnosed with IM if they fulfilled the Hoagland criteria; that is 
presenting with a triad of fever, pharyngitis, and lymphadenopathy, with at least a 50% 
lymphocytosis, and confirmed by positive serological test(Hoagland 1975, Ebell 2004). 
Patients were excluded if they were allergic to penicillin and therefore would get an 
alternative to Benzylpenicillin, as is the standard of care. Pregnant patients and those 
with airway emergencies were also excluded. Patients diagnosed with CMV 
mononucleosis or other mononucleosis like infections were also excluded. A Cochrane 
review (Candy and Hotopf 2006) found that there was no evidence for the routine 
treatment of IM with steroids, however it was felt that this may be a confounder, 
therefore initially these patients were also to be excluded. However another review 
recommended steroids for all patients presenting with sore throats (Hayward et al. 
2012), and although Emergency department staff were educated about the study, a 
number of patients who were given steroids in the Emergency department were 
included in the study. Steroids were not continued once the patients were admitted and 
ancillary analysis was performed on these patients. 
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 3.2.2 Metronidazole dosing 
Metronidazole is a well established nitroimidazole antibiotic. A standard dose of 500mg 
TDS intravenously was given at regular interval at the same time as the standard of care 
antibiotic, Benzylpenicillin. Benzylpenicillin is given to patients with IM who are not 
penicillin allergic to prevent a bacterial superinfection. It is part of the standard of care, 
including supportive treatment with intravenous hydration, antipyretics and analgesics, 
which all patients received. No placebo was given as nurses on the hospital ward gave 
both the antibiotics at the same time.   
 
3.2.3 Outcomes 
The primary outcome measured was the difference in length of stay in days in the 
hospital. Length of stay (LOS) was acquired from the case report form and verified by 
the Hospital In Patient Enquiry (HIPE) system. Patients were discharged when the 
consultant in charge of their care felt that they had made a sufficient recovery and were 
unlikely to represent or require further inpatient care.  Secondary outcomes included 
reduction in inflammatory markers, (white cell count, WCC) and duration of high 
temperature (Over 38 degrees Celsius).  
 
3.2.4 Sample size calculation 
The specified elements of the sample size calculation that we would want to include in 
our trial report are a significance level of 5%, power of 80%, a baseline mean hospital 
stay of 4.37 days, (using data from a recently published study on the same population 
(Lennon et al. 2013b)), and a decrease in hospital stay by 25%. The target total was 48 
patients. Interim analysis was not carried out.  
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3.2.5 Randomisation 
Randomisation was carried out by simple randomization, and allocation was concealed 
from the patient. The first author carried out enrolment, randomization and allocation 
concealment. Patients were blinded to their treated arm. Both received multiple 
injections and nurses were asked not to inform patients of which arm the patient was 
in.  
 
3.2.6 Statistical analysis  
Statistical analysis on the difference in length of stay between the arms of the trial will 
be calculated, along with 95% confidence intervals, using the statistical program SPSS. 
Subgroup analysis was carried out on those who received steroids. CONSORT 
(CONsolidated Standards of Reporting Trials) guidelines were followed during the trial 
(Moher et al. 2010).  
 
3.2.7 Ethics 
Ethical permission was sought and granted by the Mid-Western Regional Ethics 
Research committee and all patients signed an informed consent prior to being enrolled 
in the trial.  
Chapter 3                                                RCT: Metronidazole in Infectious 
Mononucleosis 
 46 
3.3 Results 
3.3.1 Recruitment 
Fifty-one patients were admitted under the Ear Nose and Throat service with Infectious 
Mononucleosis during the trial period. Forty-two of these patients were enrolled in the 
trial. Eight patients were excluded, 5 as they were allergic to penicillin, 2 due to being 
under the age of 15, and one patient with an airway emergency. A single patient refused 
to partake in the trial. Age eligible patient were recruited between the 5th January 2010 
and the 11th April 2012. Patients were followed as in-patients and therefore there was 
no loss to follow up.  Three patients were started on Metronidazole who were initially 
in the control group, but failed to show any sign of improvement. These patients were 
analysed in their original group (Fig 11). The trial was stopped when sufficient numbers 
were recruited to allow statistical analysis. 
 
Figure 11: Patient flow (CONSORT) diagram 
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 3.3.2 Patient Characteristics 
Both groups had a similar age profile, with a mean age of 18.26 (Fig 12) and 18.56 (Fig 
13) in the intervention and control arm respectively.  
 
 
Figure 12: Age on admission-metronidazole group 
 
There was a larger amount of females in the standard of care group but this was not 
found to be significant (Chi-square, p=0.352). Both groups were found to be 
symptomatic for a similar period prior to admission (6.5 and 6.3 mean days) and had 
attended their primary care physician who had prescribed antibiotics for on average 
3.25 and 3 days prior to admission to hospital. 
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Figure 13: Age on admission-standard of care group 
 
Fifteen in the treatment arm and 17 in the control arm had received antibiotics prior to 
admission. No significant difference in these baseline values was found between the 
two groups (Table 7). 
 
Table 7: Baseline characteristics 
 Metronidazole Standard of Care p-Value 
Age (Mean, SD) 18.26 (2.2) 18.56 (2.03) 0.643 
Age (Range) 15-23 years 15-22 years  
Male  11 8  
Female 10 13  
Days Symptomatic prior to 
admission (mean) 
6.5 6.3 0.872 
Attended GP prior to admission 15 17  
Chapter 3                                                RCT: Metronidazole in Infectious 
Mononucleosis 
 49 
Days receiving antibiotic prior to 
admission (mean) 
3.25 3 0.649 
 
3.3.3 Outcomes  
The primary endpoint in the study was the difference in length of stay between the two 
groups. This was significantly less in the Metronidazole group with a mean of 3.67, 
compared to a mean of 4.67 in the standard of care group (p=0.032). There were small 
differences in the amount of days the patients remained febrile and the rate of decrease 
in the WCC, however neither of these were significant. We also found no significant 
difference in the LOS between those that had received or not received steroids, and no 
significant difference between the sexes or those that presented less than 5 days after 
the symptoms began or those that presented later than this (Table 8).  
 
Table 8: Results of the RCT 
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No adverse effects from Metronidazole were reported and there were no complications 
due to the disease process in either group.  
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3.4 Discussion 
Infectious Mononucleosis caused by Epstein Barr virus was in its infancy as a 
recognisable disease process when Hedström et al suggested that the pharyngo-
tonsillitis elements of the illness were reminiscent of an anaerobic infection. A number 
of studies were therefore undertaken to examine the possible role of Metronidazole in 
the treatment of IM. The majority of these studies support the contention that 
Metronidazole does indeed have a beneficial action in those with severe IM (Hedstrom 
et al. 1978, Hedstrom 1980, Davidson et al. 1982, Dalmau et al. 1990), with a single 
paper showing no significant effect (Spelman and Newton-John 1982). The results of 
our study here concur with the majority of those previously undertaken that 
Metronidazole shortens the duration of severe IM.  
 
3.4.1 Limitations of the study 
The limitations of this study include its small size, and therefore are confidence 
intervals are rather wide, however they do not cross 0. The trial is similar in size to the 
larger of the previously published studies on the same subject (Hedstrom 1980, 
Spelman and Newton-John 1982). Due to their small size and that the methods differ 
between them substantially, meta-analysis of these studies may be misleading(Walker 
et al. 2008). The lack of publications with ‘negative’ results for Metronidazole 
treatment may be due to publication bias towards those with ‘positive’ results. From a 
recently published study on the epidemiology of the same population (Lennon et al. 
2013b),  a mean of 18.5 patients a year were admitted over the previous 20 years at this 
institution. Therefore recruitment of 42 patients out of a possible 51 patients in 28 
months was deemed satisfactory.   
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Further weaknesses included the lack of a placebo. The trial was carried out within a 
clinical setting with no added funding. Medical and nursing staffs were educated about 
the study and efforts were made to conceal the treatment allocation from patients. There 
was also a very small trial team, with the primary author carrying out most of the 
recruitment, allocation, randomization, data gathering and inputting, as well as the 
statistical analysis, thus leading to the risk of multiple biases, including reporting bias 
and multiplicity. Randomization was also done by simple randomization where, 
permuted blocked may have been a better choice initially. However baseline values in 
both groups are similar.  
 
3.4.2 Synopsis of key findings 
Length of stay was used as our primary outcome as it could be reliably measured and 
verified by hospital records, and compared against other studies. The patients’ fitness 
for discharge was used as our main endpoint as an overall assessment of their wellbeing, 
as no validated scoring system for IM exists to our knowledge. We also examined 
whether Metronidazole had an effect on the persistent high temperatures in these 
patients. We used antipyretics in all the patients, as this was the standard of care and a 
stipulation of our ethical approval. In some of the older papers (Hedstrom 1980), 
antipyretics were avoided to fully assess the effect of Metronidazole. Whilst in hospital 
patients received regular antipyretics and few patients had persistent temperatures, with 
no significant difference seen between the two groups. We also did not see a significant 
difference between the groups in the rate at which their WCC fell. However it has been 
noted that in treating infectious diseases the “pursuit of the holy grail of laboratory 
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markers continues. The clinical constellation of the context and history of illness, 
findings on examination and simple laboratory tests together trump any individual test” 
(Long 2006).   
3.4.3 External validity 
The results of this trial can be applied to a small but noteworthy cohort of patients. That 
is, those with severe IM that require admission to hospital. A large amount of patients 
that develop IM are likely to be treated in the community and a study on the benefits of 
Metronidazole on these patients would also be interesting.  
 
3.4.4 Comparison to other studies  
The results of our trial concur with four of the previously published reports on the use 
of Metronidazole in IM. We noted a mean of a day shorter in hospital between our two 
groups. Hedström et al noted a ‘significantly shorter period of tonsillitis’ (Hedstrom et 
al. 1978) with most of their patients having no signs of tonsillitis after 3 days in those 
treated with metronidazole compared to 4-7 days in the controls. In a follow up study 
they again noted that those treated with Metronidazole were significantly better on the 
third day (Hedstrom 1980).  A further two papers (Davidson et al. 1982, Dalmau et al. 
1990), one with a paediatric population, demonstrated a rapid regression of symptoms 
in uncontrolled small groups. In our study, three patients were started on Metronidazole 
that were originally in the control group, as they failed to improve or had deteriorated. 
The three patients subsequently made a rapid recovery. A paper by Spelman et al 
(Spelman and Newton-John 1982) also demonstrated that patients were greatly 
improved by the fourth day but they found no significant difference between the 
treatment and control group (Table 3). 
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Table 9: Literature review-Previously published reports on the use of Metronidazole in IM. 
Name Year 
Number of patients 
Result Comment 
Intervention Control 
Hedström(Hedstrom 
et al. 1978) 
1978 16 10 
‘Significantly 
shorter’ 
No 
penicillin 
Hedström(Hedstrom 
1980) 
1980 21 19 
3rd day 
significantly 
better 
No 
antipyretics 
given 
Davidson(Davidson 
et al. 1982) 
1982 5 0 
All improved 
shortly after 
treatment 
Paediatric 
population 
Spelman(Spelman 
and Newton-John 
1982) 
1982 20 20 
No significant 
difference 
 
Dalmu(Dalmau et 
al. 1990) 
1990 4 0 
Rapid clinical 
improvement 
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A much greater number of anaerobic bacteria have been found on the surface of tonsils 
during an infection with IM than when the patient has recovered from the disease 
(Brook and de Leyva 1994). It has also been shown that EBV exerts a transient 
suppression of immunoglobulin-coating of bacteria harboured on the tonsillar surfaces, 
with consequent abundant bacterial attachment to the epithelial cells and massive 
bacterial colonization on the palatine tonsils and penetration into the epithelial cells 
(Stenfors and Raisanen 1996, Stenfors et al. 2001). The role of anaerobic bacteria in 
the pharyngitis associated with IM is difficult to elucidate because these organisms are 
part of the normal oropharyngeal flora. However it has been postulated that 
Metronidazole may help to hasten recovery in these patients by suppressing of the oral 
anaerobic flora that might contribute to the inflammatory process induced by the 
Epstein–Barr virus (Brook 2005).  
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3.5 Conclusions  
Our study has again demonstrated that Metronidazole has a role to play in severe 
Infectious Mononucleosis.  We were able to demonstrate that patients randomised to 
metronidazole had a significantly shorter hospital stay than those who were treated by 
the standard of care. More trials on a larger scale and possibly in an outpatient setting 
are required.  
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THE BOTTOM LINE 
• Infectious mononucleosis is a clinical diagnosis, caused by Epstein-Barr virus 
in 90% of cases, although in some patients (pregnancy, high risk HIV 
population) further investigations are warranted 
• Treatment should be supportive, with steroids given only in cases of airway 
compromise 
• Treatment with antiviral agents has yet to be shown to be of benefit 
• Patients wanting to return to contact sports before one month should undergo 
abdominal ultrasonography to rule out splenomegaly 
• Splenic rupture should be considered with any abdominal pain in infectious 
mononucleosis 
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4.1 Introduction  
Infectious mononucleosis is commonly seen in both the community and the hospital 
setting. Patients usually present with a sore throat and often presume that an antibiotic 
is required. It is therefore important to dispel the many myths relating to the condition 
with appropriate patient education. Knowledge of the clinical course of the disease, as 
well as potential complications, is paramount. In an information age, difficult questions 
may arise for a general practitioner, emergency doctor, or trainee in ear, nose, and throat 
medicine. The aim of this review is to assist those who encounter infectious 
mononucleosis in the adolescent and adult population 
 
 
Chapter 4                                                 Infectious Mononucleosis: BMJ review 
 60 
4.2 Sources and selection criteria 
We performed an electronic search through Medline, Scopus, Google Scholar, the 
Cochrane Database of Systematic Reviews, and the Cochrane central register of 
controlled trials using the search terms “infectious mononucleosis”, “glandular fever”, 
“Epstein-Barr virus”, “corticosteroids”, and “acyclovir”. The search was limited to 
articles in English. We excluded studies carried out primarily on children. Priority was 
given to data from meta-analyses, reviews, and randomised controlled trials. Research 
on infectious mononucleosis was also given priority over articles exclusively relating 
to Epstein-Barr virus. We also examined guidelines produced by the US Centre for 
Disease Control and Prevention and the UK National Institute for Health and Care 
Excellence, as well as clinical trials registries of the United States, United Kingdom, 
and European Union (Clinical trials for Infectious Mononucleosis, EU Clinical Trials 
Resigter  2014, ClinicalTrials.gov, U.S. National Institutes of Health  2014, Current 
controlled trials, International Standard Randomised Controlled Trial Number 
Register  2104). 
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4.3 What is infectious mononucleosis and what causes it? 
It would be most accurate to consider infectious mononucleosis as a non-genetic 
syndrome, defined by the classic triad of fever, pharyngitis, and cervical 
lymphadenopathy, where lymphocytosis is also present. For many doctors the terms 
Epstein-Barr virus and infectious mononucleosis are synonymous. Epstein-Barr virus 
causes approximately 90% of the cases of infectious mononucleosis, with the remainder 
due largely to cytomegalovirus, human herpes virus 6, toxoplasmosis, HIV, and 
adenovirus (Henle et al. 1974, Hurt and Tammaro 2007). The World Health 
Organization’s ICD-10 (international classification of diseases, 10th revision) has four 
subheadings for infectious mononucleosis (or B27 in the manual (International 
Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-
10)  2010)): infectious mononucleosis associated with Epstein-Barr virus (B27.0), 
cytomegalovirus infectious mononucleosis (B27.1), other infectious mononucleosis 
(B27.8), and infectious mononucleosis unspecified (B27.9). To confuse things further 
the multiple synonyms for infectious mononucleosis (glandular fever, monocytic 
angina, Pfeiffer’s disease, Filatov’s disease, Drusenfieber, and even the kissing disease) 
are still included in ICD-9, which will be in use in the United States until 1 October 
2015 (ICD-9-CM Diagnosis Code 075  2012). 
 
The Epstein-Barr virus is a ubiquitous herpes virus, with more than 90% of the world’s 
population infected by adulthood (Henle et al. 1969). The virus is one of our most 
effective parasites (Macsween and Crawford 2003) and remains as a lifelong, latent 
infection, by integrating itself into the life cycle of healthy B lymphocytes (Thorley-
Lawson et al. 1996, Babcock et al. 1998).There is persistent low grade replication and 
the virus is shed intermittently into pharyngeal secretions, particularly saliva, through 
which it is transmitted. These low titres of infectious virus account for the low to 
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moderate contagiousness (Niederman et al. 1976, Yao et al. 1985) of the disease and 
the apparent requirement of intimate contact for disease transmission (Andiman 2006). 
During an active infection the viral load may be increased, and therefore some 
precautions about contact should be mentioned (cough etiquette, hand hygiene, kissing, 
sharing food or utensils); however, as most of the population is positive for Epstein-
Barr virus, special precautions against transmission are not necessary in most cases 
(Luzuriaga and Sullivan 2010). Childhood infection, which is usually subclinical, is 
associated with poor hygiene and over-crowding. In lower socioeconomic groups most 
of the population will have acquired immunity by adolescence (Schuster and Kreth 
1992) After an incubation period of four to seven weeks (Hoagland 1964), EBV 
infection of adolescents or adults results in IM in up to 70% of cases(Tattevin et al. 
2006). Most symptoms tend to resolve in two to four weeks, although approximately 
20% of patients continue to mention a sore throat at one month (Rea et al. 2001). In one 
study, patients with severe infectious mononucleosis who were admitted to hospital for 
intravenous hydration required a significantly longer stay than those admitted with 
bacterial tonsillitis (Lennon et al. 2013b). Reactivation of Epstein-Barr virus may occur 
in immunocompromised patients (Ternak 2003) and, rarely, in immunocompetent 
patients, which may lead to Epstein-Barr virus associated lymphoproliferative 
conditions. These are a heterogeneous group of diseases that often need to be treated 
with chemotherapy (Tse and Kwong 2015). Diagnoses depend on the specific disease 
but are often associated with an increased viral load (Ok et al. 2015). Chronic active 
Epstein-Barr virus infection is a rare condition that is typified by severe, chronic, or 
recurrent infectious mononucleosis-like symptoms after a well-documented primary 
infection with Epstein-Barr virus in a previously healthy person (Macsween and 
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Crawford 2003). Chronic active Epstein-Barr virus infection is occasionally associated 
with the development of lymphoma (Kanegane et al. 2002). 
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4.4 How is it diagnosed? 
Infectious mononucleosis may account for as little as 1% of patients who present with 
a sore throat to their doctor (Bisno 2001). Non-specific prodromal symptoms of fever, 
chills, and malaise may be seen in infectious mononucleosis. These symptoms may also 
be present in cases of viral pharyngitis, commonly caused by rhinovirus, adenovirus, 
and coronavirus. Whereas these viruses generally give rise to symptoms of a common 
cold (Bisno 2001), clinically infectious mononucleosis should be suspected in anyone 
who presents with fever, pharyngitis, and cervical lymphadenopathy (the classic triad 
of fever, pharyngitis, and cervical lymphadenopathy) (Pfeiffer 1889). 
Lymphadenopathy may be prominent in both the anterior and the posterior triangles of 
the neck, which distinguishes infectious mononucleosis from bacterial tonsillitis (where 
the lymphadenopathy is usually limited to the upper anterior cervical chain). These 
signs were found in 98% of patients with a diagnosis of infectious mononucleosis 
(Hoagland 1975). Other common physical signs include palatal petechiae (25-50%), 
splenomegaly (8%)(Rea et al. 2001), hepatomegaly (7%), and jaundice (6-8%) 
(Hoagland 1960a), with a transitory derangement of liver function tests (in particular 
increased aspartate aminotransferase and alanine aminotransferase levels, returning to 
normal after 20 days) seen in 80-90% of patients (Kofteridis et al. 2011). Anecdotally, 
a “whitewash”’ exudate on the tonsils may also help to distinguish infectious 
mononucleosis from the more speckled exudate of bacterial tonsillitis and the erythema 
of a viral pharyngitis that is void of exudate. In the primary care setting a clinical 
diagnosis alone may be sufficient to allow adequate management of a patient. However, 
should a definitive diagnosis be sought, the Hoagland criteria states that in patients 
presenting with clinically suspected infectious mononucleosis and at least a 50% 
lymphocytosis (10% atypical), the diagnosis should be confirmed by the heterophile 
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antibody (monospot) test (Hoagland 1975).  Using a lower rate of lymphocytosis (Wolf 
et al. 2007, Biggs et al. 2013) has been shown to give a greater rate of false negative 
results (Table 10) (Lennon et al. 2010, Lennon et al. 2013a, Lennon et al. 2014b) 
Table 10: Diagnostic test for Infectious Mononucleosis 
 
 
The heterophile test may also be falsely negative in up to 25% of adults in the first week 
of symptoms (Hoagland 1975, Hurt and Tammaro 2007). It is not always necessary to 
definitively diagnose a cause for infectious mononucleosis, but specific antibody tests 
are available. Patients are considered to have a primary Epstein-Barr virus infection if 
they are positive for antiviral capsid antigen IgM but do not have antibodies to Epstein-
Barr virus nuclear antigen, which would suggest past infection. Levels of antiviral 
capsid antigen IgG will also increase in the acute phase and persist for the rest of the 
patient’s life, whereas the antiviral capsid antigen IgM will disappear after 4-6 weeks. 
The presence of antiviral capsid antigen IgG and Epstein-Barr virus nuclear antigen 
suggest past infection (Centers for Disease Control and Prevention (CDC) Epstein-
Barr Virus and Infectious Mononucleosis, Laboratory Testing  2014). A recent review 
found that real time polymerase chain reaction and measurement of Epstein-Barr virus 
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viral load provide useful tools for the early diagnosis of infectious mononucleosis in 
cases with inconclusive serological results (Vouloumanou et al. 2012). In a small 
number of cases, where the patient is either pregnant or in a high risk group for HIV 
infection (injecting drug user or men who have sex with men), further testing for 
cytomegalovirus, HIV, and other possible causes for infectious mononucleosis should 
be undertaken (Sudarshi et al. 2008, Rayment et al. 2014). Figure 14 presents an 
algorithm for diagnosing infectious mononucleosis (Tsaparas et al. 2000). 
 
Figure 14: Suggested algorithm for diagnosing Infectious Mononucleosis 
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4.5 How is it treated? 
Infectious mononucleosis is a viral illness in most cases, and as such it can be treated 
with rest, hydration, analgesia, and antipyretics. Inadvertent treatment with ampicillin 
results in a fine macular rash in 90% of patients (Macsween and Crawford 2003). This 
should be distinguished from an urticarial rash seen in an allergic reaction. Studies have 
shown that symptoms experienced by patients are more severe for infectious 
mononucleosis than for bacterial tonsillitis (Lennon et al. 2013b). Antiviral treatment 
with acyclovir has been shown to significantly decrease the rate of oropharyngeal 
Epstein-Barr virus shedding (Torre and Tambini 1999). Some early trials found a 
significant positive overall effect in cases of infectious mononucleosis treated with 
acyclovir (Andersson et al. 1986) and that it was useful in severe cases, with airway 
compromise. However, a meta-analysis of five studies found no evidence to support its 
use in the acute setting: an improvement in oropharyngeal symptoms was observed in 
25 out of 59 (42.4%) patients treated with acyclovir and in 18 out of 57 (31.6%) control 
patients (odd ratio 1.6, 95% confidence interval 0.7 to 3.6; P=0.23) (Torre and Tambini 
1999). Other antiviral treatments such as valaciclovir and ganciclovir (Adams et al. 
2006) have shown some promise in the treatment of severe infectious mononucleosis 
and its complications and immunocompromised people. Two trials are in progress 
(ClinicalTrials.gov, U.S. National Institutes of Health  2014), but at present the routine 
use of both drugs is not advocated (Rafailidis et al. 2010). Anaerobic antibacterial 
agents such as metronidazole have been suggested to hasten recovery in infectious 
mononucleosis by suppression of the oral anaerobic flora that contribute to the 
inflammatory process (Brook 2005). This finding was borne out in some clinical 
studies(Hedstrom et al. 1978, Davidson et al. 1979, Hedstrom 1980, Davidson et al. 
1982, Marklund et al. 1984, Dalmau et al. 1990), with a recent randomised controlled 
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trial showing the beneficial effects of metronidazole in severe infectious mononucleosis 
by shortening hospital stays(Lennon et al. 2014a). Larger trials may be required before 
the use of metronidazole is routinely recommended. 
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4.6 Are steroids of use in the treatment of infectious mononucleosis? 
Several early reports supported the use of corticosteroids in the treatment of infectious 
mononucleosis (Prout and Dalrymple 1966). Further trials showed these effects to be 
short lived, with no significant difference between the control and intervention arm 
(Tynell et al. 1996). A Cochrane review was therefore undertaken, which concluded 
that there was insufficient evidence and the trials were too few, heterogeneous, and of 
poor quality to recommend steroid treatment for symptom control in glandular fever 
(Candy and Hotopf 2006). Another more recent Cochrane review concluded that 
corticosteroids increased the likelihood of both resolution and improvement of pain in 
participants with sore throat (Hayward et al. 2012); however, this review excluded 
publications on patients with a diagnosis of infectious mononucleosis. Steroid treatment 
should be considered in cases of airway emergency, in an attempt to temporise or 
preclude the need for intubation or tracheotomy (McGowan et al. 1992). Despite these 
guidelines, the use of corticosteroids remains widespread on a day to day basis 
(Thompson et al. 2005). Several reports have mentioned the adverse effects of 
corticosteroid use in infectious mononucleosis, including cases of peritonsillar 
cellulitis, acute onset diabetes mellitus, and neurological sequelae (Candy and Hotopf 
2006). 
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4.7 Does infectious mononucleosis lead to chronic fatigue syndrome? 
Chronic fatigue syndrome is defined as severe fatigue and disabling musculoskeletal 
and cognitive symptoms without another explanation that lasts for at least six months 
and results in severe impairment in daily functioning (Fukuda et al. 1994). There has 
been much debate about the cause of this disorder. Some authors suggest that it is 
precipitated by an acute infection, such as infectious mononucleosis, as many patients 
relate the onset of their illness to an initial infection from which they never recovered 
(Wessely et al. 1995). Prospective studies have reported an incidence of chronic fatigue 
syndrome of 7.3-12% in adults six months after infectious mononucleosis (White et al. 
2001, Moss-Morris et al. 2011). However, the relation between chronic fatigue 
syndrome and infectious mononucleosis is still questionable. A study of over 1300 
patients diagnosed as having infectious mononucleosis by serology, found that although 
10% of patients reported fatigue none fulfilled the criteria for chronic fatigue syndrome 
(Table 11) (Petersen et al. 2006). 
 
Table 11: Infectious Mononucleosis and Chronic Fatigue Syndrome 
 
 
 The cause of chronic fatigue syndrome is likely to be multifactorial. A trial that 
compared activity with imposed bed rest in the management of infectious 
mononucleosis found that those patients who were allowed out of bed as soon as they 
Chapter 4                                                 Infectious Mononucleosis: BMJ review 
 71 
felt able reported a quicker recovery (Candy et al. 2002) A brief intervention at the time 
of diagnosis of infectious mononucleosis to allay fears of a prolonged disease may help 
to prevent the development of chronic fatigue syndrome (Candy et al. 2004). A recent 
editorial commented that chronic fatigue syndrome is unlikely to be a consequence of 
Epstein-Barr virus but a heterogeneous family of disorders arising from a constellation 
of pathophysiological causes('Chronic fatigue syndrome: going viral?'  2010). 
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4.8 When is it safe to return to sports? 
Splenomegaly, evident on ultrasonography if not on palpation, occurs in almost all 
cases of infectious mononucleosis, and the risk of splenic rupture has been well 
established (Dommerby et al. 1986). A considerable number of 15-21 year olds will 
have infectious mononucleosis every year (Lennon et al. 2013b) and many of this 
population will be involved in contact sports (Nieman 1994). Strenuous or contact 
sports (for example, football, gymnastics, rugby, hockey, lacrosse, wrestling, diving, 
and basketball) or activities associated with increased intra-abdominal pressure, such 
as weightlifting, may put athletes at most risk (Auwaerter 2004). 
 
Although recommendations of when to return to sport range from three (Kinderknecht 
2002), four (Hoagland and Henson 1957), eight, and even up to 24 weeks (Moolenaar 
et al. 1988), no clinical guidelines are specific to infectious mononucleosis. The 
incidence of splenic rupture is less than 1% (Rea et al. 2001) and most occur in the 
initial three weeks of infectious mononucleosis, although cases have been described 
much later (Putukian et al. 2008).  
 
Cases of spontaneous splenic rupture have also been described in the literature and 
doctors should have a high index of suspicion when abdominal pain is reported in the 
setting of infectious mononucleosis(Raman et al. 2014). A recent study involved 
weekly ultrasound examinations until resolution of splenomegaly. A mean increase in 
splenic length of 33.6% was observed, with a peak in enlargement on average 12.3 days 
from the onset of clinical symptoms. Most cases of splenomegaly had resolved by 4-6 
weeks and there was a predictable rate of splenic regression of approximately 1% each 
day after reaching peak enlargement (Hosey et al. 2008). Similar results were reported 
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in another paper, with normalisation of spleens at one month in 84% of participants 
(O'Connor et al. 2011). One study recommended that athletes wanting to return to 
contact sport at 3-4 weeks should have an ultrasound examination to ensure that the 
spleen had returned to normal size (O'Connor et al. 2011). A systematic review 
published in 2014 advocated individualised recommendations for athletes (Becker and 
Smith 2014), and future work in this area may concentrate on splenic volume to allow 
a more accurate assessment of splenomegaly and risk. 
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4.9 Is multiple sclerosis caused by infectious mononucleosis? 
There is evidence that a history of infectious mononucleosis significantly increases the 
risk of multiple sclerosis (Thacker et al. 2006) and that this association is far stronger 
than with other common childhood infections or afflictions.  A meta-analysis concluded 
that the risk of multiple sclerosis seems to be greatest in those who were infected with 
Epstein-Barr virus at a later age (incidence begins to increase in adolescence, peaks 
around age 25 to 30 years, and declines to nearly zero by age 60) (thus developing 
infectious mononucleosis), with moderate risk for those infected with Epstein-Barr 
virus in early childhood, and close to zero risk in those not infected (Thacker et al. 
2006) (Fig 15).  
 
 
Figure 15: Incidence of multiple sclerosis by Epstein-Barr virus infection 
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A more recent meta-analysis showed that Epstein-Barr virus is present in 100% of cases 
of multiple sclerosis and therefore it has been suggested that the virus is not only a risk 
factor but also a prerequisite of multiple sclerosis (Pakpoor et al. 2013). Whether the 
association between multiple sclerosis and Epstein-Barr virus demonstrates a causal 
relation is, however, strongly debated (Pakpoor et al. 2013). 
 
Although controversial, if proponents of the infectious mononucleosis-multiple 
sclerosis theory are correct, a vaccine against Epstein-Barr virus in theory could 
eradicate multiple sclerosis. In the only phase II trial of an Epstein-Barr virus vaccine 
in humans, rates of infectious mononucleosis were reduced in adults who were 
seronegative for Epstein-Barr virus, but the vaccine did not affect the rate of Epstein-
Barr virus infection (Cohen et al. 2013). The development of a vaccine is challenging 
for several reasons, not least the long period between primary infection with Epstein-
Barr virus and the development of many Epstein-Barr virus related tumours or multiple 
sclerosis (Cohen et al. 2011). To add further to the controversy it has been suggested 
that in lieu of a vaccine, a smaller, but still substantial, number of cases of multiple 
sclerosis could be prevented by exposing children to Epstein-Barr virus infection before 
adolescence (Thacker et al. 2006).  
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4.10 Is there an increased risk of lymphoma or other cancers after IM? 
The association of Epstein-Barr virus with malignancies such as Burkitt’s lymphoma 
(Gromminger et al. 2012) in children and nasopharyngeal carcinoma (Song and Yang 
2013) are well established. This review, however, focuses on patients presenting with 
infectious mononucleosis and it can be difficult to differentiate studies on Epstein-Barr 
virus and infectious mononucleosis about the risk of future malignancies. Two large 
Scandinavian cohort studies found a 2.55 to 2.83 times increased risk of Hodgkin’s 
lymphoma in patients with a diagnosis of infectious mononucleosis by heterophile 
antibody tests (Rosdahl et al. 1974, Hjalgrim et al. 2007). The results were similar in a 
recent British record linkage paper, which found a 3.44 risk ratio of Hodgkin’s 
lymphoma in the infectious mononucleosis cohort (Goldacre et al. 2009).  
 
A review on Epstein-Barr virus related malignancies from 2014 commented that 
Hodgkin’s lymphoma is the only Epstein-Barr virus related malignancy, other than 
nasopharyngeal carcinoma, for which there is a body of evidence accumulated over 
time that establishes a strong association (Coghill and Hildesheim 2014). For other 
malignancies, a large prospective study found no clear association between a history of 
clinical infectious mononucleosis and risk of invasive breast cancer(Massa et al. 2012), 
and one of the cohort studies found that lung cancer was significantly less likely in the 
cohort with infectious mononucleosis (Hjalgrim et al. 2000). 
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4.11 Can infectious mononucleosis cause any complications? 
Infectious mononucleosis in most cases resolves over a period of weeks, but may 
occasionally be exacerbated by a wide variety of complications. Neurological disorders 
may occur in 1-5% of patients (Jenson 2000). Theses include encephalitis, 
meningoencephalitis, seizures, optic neuritis, sudden sensorineural hearing loss, 
idiopathic facial palsy, and Guillain-Barré syndrome among others(Connelly and 
DeWitt 1994). Haematological complications are more common, in particular 
haemolytic anaemia (3%) and thrombocytopenia (25-50%) (Jenson 2000), but also 
rarely aplastic anaemia, pancytopaenia, and agranulocytosis. Other rare acute 
complications include myocarditis, pericarditits (Sabbatani et al. 2012), pancreatitis, 
interstitial pneumonia, rhabdomyolysis, and psychological complications (“Alice in 
Wonderland” syndrome). The strength of association of infectious mononucleosis with 
many of these complications is based on scattered case reports, and the evidence of 
causation in many instances is unconvincing (Jenson 2000). A thorough list of 
complications can be found at www.cdc.gov/epstein-barr/hcp.html. 
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4.12 Ongoing research 
• The use of splenic volume to assess splenomegaly in infectious mononucleosis 
(proposed) 
• Anaerobic antibiotics in infectious mononucleosis (proposed) 
• Vaccination against Epstein-Barr virus (proposed—unaware of any active 
research) 
• The pathogenesis of multiple sclerosis (several studies listed on 
ClinicalTrials.gov) 
• Molecular analysis of Epstein-Barr virus related tumours and the role of the 
virus in ontogenesis (multiple studies listed on ClinicalTrials.gov) 
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4.13 Additional educational resources 
4.13.1 Resources for healthcare professionals 
• Candy B, Hotopf M. Steroids for symptom control in infectious mononucleosis. 
Cochrane Database Syst Rev 2006;3:CD004402 (a systematic review on the use 
of steroids in IM) 
• Centre of Disease Control and prevention. Guidelines on laboratory testing for 
Epstein-Barr virus and infectious mononucleosis (www.cdc.gov/epstein-
barr/laboratory-testing.html) (The CDC’s guidelines on diagnosing IM) 
• NHS Clinical Knowledge Summaries on glandular fever 
(http://cks.nice.org.uk/glandular-fever) (a National Health Service resource on 
IM) 
• BMJ best practice guidelines (http://bestpractice.bmj.com/best-
practice/monograph/123.html) (a helpful online resourse from the British 
Medical journal) 
 
4.13.2 Resources for patients 
• Medline plus. Infectious mononucleosis 
(www.nlm.nih.gov/medlineplus/infectiousmononucleosis.html#cat27) 
• NHS Choices. Glandular fever (www.nhs.uk/conditions/Glandular-
fever/Pages/Introduction.aspx) 
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4.14 Tips for general practitioners 
General practitioners may see as many as 10 new cases of infectious mononucleosis a 
year (Candy et al. 2002). Although most patients will have mild symptoms, referral 
should be made to a secondary or tertiary centre in the following instances: 
• Airway compromise 
• Suspected splenic rupture 
• Failure of supportive treatments (which may be indicated by the inability to 
swallow fluids or even saliva, and may occur in approximately 10% of patients) 
(Hoagland 1960b) 
• Immunosuppressed or post-transplant patients 
• Patients with infectious mononucleosis but negative for Epstein-Barr virus 
antibodies
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INTRODUCTION 
This section of the thesis comprises of a number of minor publications that have come 
about, and are directly related, to the core papers of this study. Three of the articles are 
“Letters to the Editor”, one directly responding to a letter written in relation to the 
publication of Chapter 1 of this thesis. Another was a summary of our recent research 
in this area that was submitted to another Journal, in response to an article published on 
a similar subject. The third publication was again a response to research published by 
other authors on a similar topic to our paper in Chapter 1, but who had used the absolute 
lymphocyte count rather than the L/WCC ratio. We responded to this by re-running our 
calculations on our 1000 patients with Monospot results, and re-presented our findings 
as a short research note. The final article in this section is an invited review of a meta-
analysis carried out to review the use of steroids in Infectious Mononucleosis.  
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5.1 Response to Hanna Re: The diagnosis of infectious 
mononucleosis by Lennon et al. in a previous issue. 
 
Paul Lennon1, 2, James Paul O’Neill2, John E. Fenton1, Tadhg O’Dwyer2 
1. Department of Otolaryngology, Head and Neck Surgery, University Hospital Limerick 
2. Department of Otolaryngology, Head and Neck Surgery, Mater Misericordiae University 
Hospital, Dublin  
 
5.1.1 Background to the publication 
In response to our publication of “Challenging the use of the lymphocyte to white cell 
count ratio in the diagnosis of infectious mononucleosis by analysis of a large cohort 
of monospot test results” in Clinical Otolaryngology, B. Hanna wrote the letter below 
to the editor (Hanna 2012). The authors main concern was proliferation of notion that 
IM and EBV are synonymous, in particular that this may lead the missed oppurtunities 
in the early diagnosis of HIV. Hanna’s letter can be seen on the following page and our 
response on the subsequent one. 
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Figure 16: "Re: The diagnosis of infectious mononucleosis" by B. Hanna 
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5.1.2 Letter to the Editor 
“Sir, 
The aim of our study (Lennon et al. 2010) was not to further the misconception that 
EBV infection is synonymous with Epstein– Barr virus, but rather that the use of 
Lymphocyte to white cell count alone would lead to infectious mononucleosis (IM) 
being diagnosed as bacterial tonsillitis (BT) in up to one in seven case. Our paper was 
undertaken in response to an earlier paper by Wolf et al (Wolf et al. 2007) who 
suggested that a lymphocyte to white cell count (L ⁄ WCC) ratio of 0.35 could be used 
as a screening tool for IM. Our paper with much larger numbers demonstrated that the 
most appropriate diagnostic algorithm should remain, as suggested by Hoagland, that 
patients presenting with fever, pharyngitis and lymphadenopathy, with lymphocytosis 
and confirmed by positive serological test, can be diagnosed with IM (Hoagland 1975). 
 
I do think that the above observation is an important one; however, we need to 
distinguish between the relatively common occurrence of an adolescent presenting with 
a sore throat against the rare occasions where these are accompanied by either the 
patient being pregnant or being in high-risk groups, as per Sudarshi et al (Sudarshi et 
al. 2008). In these cases, it would obviously be appropriate to order further 
investigations. As Hoagland warned over 50 years ago, disregarding the heterophile 
agglutination test would perpetuate considerable confusion and error, and we believe 
this summation still stands (Hoagland 1960a).” 
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5.2 Challenging the use of the absolute lymphocyte count in 
the diagnosis of infectious mononucleosis by analysis of a 
large cohort of monospot test results. 
 
Paul Lennon1, 2, James Paul O’Neill2, John E. Fenton1, Tadhg O’Dwyer2 
1. Department of Otolaryngology, Head and Neck Surgery, University Hospital Limerick 
2. Department of Otolaryngology, Head and Neck Surgery, Mater Misericordiae University 
Hospital, Dublin  
 
5.2.1 Background to the publication 
The use of a quick screening tool in infectious mononucleosis continued to interest a 
number of authors. One group proposed that the absolute lymphocyte count rather than 
the L/WCC be used as such a screening tool, and may in-fact be more accurate (Biggs 
2011). They found that all patients with an absolute lymphocyte over 4 10*9/L had IM, 
whilst no patient with a diagnosis of BT had an elevated lymphocyte count. However 
their cohort was small and therefore we further investigated the hypothesis using our 
larger database. Again the paper by Biggs is in the next page and our response is on the 
following one.  
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Figure 17: Absolute lymphocyte count and the diagnosis of IM, T.C. Biggs 
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5.2.2 Letter to the Editor 
“Sir, 
We read with interest the correspondence from T. C Biggs (Biggs 2011) in a previous 
issue espousing the use of a raised absolute lymphocyte count (> 4 x 109⁄L) as a quick 
reference tool in the diagnosis of infectious mononucleosis. This is a further step in the 
ongoing debate on a rapidly available screening tool, whilst waiting for confirmation 
of infectious mononucleosis (IM) by either definitive monospot or EBV serological 
testing. This debate was initiated by a study by Wolf et al (Wolf et al. 2007) 
recommending that the lymphocyte to white cell count (L/WCC) ratio of 0.35 should 
be used as an indicator to decide whether mononucleosis spot tests should be requested. 
With much larger numbers, our group demonstrated that L/WCC ratio is not sufficient 
to diagnose or exclude infectious mononucleosis (Lennon et al. 2010)and that one in 
seven of the patients with infectious mononucleosis would be missed leading to 
mismanagement and potentially increased morbidity. 
 
Biggs found that all the patients with glandular fever had a high white cell count greater 
than the upper limit of normal of 4 x 109⁄L. However, there were only 10 patients in 
this group. Using the data already collected from our 1000 patients in the previous 
study, we calculated the sensitivity, specificity, positive predictive value and negative 
predictive value as 61.8%, 96.8%, 95%and 71.7%, respectively (Table 12)(Fig 18). 
Table 12: Sensitivity, Specificity, PPV and NPV for absolute lymphocyte count in IM 
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Figure 18: Absolute lymphocyte count of all monospot results
 
 
 
Using a cut-off of 4 x 109⁄L, there were relatively very few patients (16) with false-
positive results, that is, those with a negative monospot but a high absolute lymphocyte 
count, giving a high specificity (96.8%) and positive predictive value (95%). There was 
however, still a large amount of patients (191) with absolute lymphocyte counts below 
4 x 109⁄L that had positive monospot results. We therefore would continue to advocate 
that the L ⁄WCC ratio or high absolute lymphocyte count should be used in conjunction 
with the Hoagland criteria(Hoagland 1975).” 
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5.3 In reference to "use of the lymphocyte count as a 
diagnostic screen in adults with suspected Epstein-Barr 
virus infectious mononucleosis". 
 
Paul Lennon1, 2, James Paul O’Neill2, John E. Fenton1, Tadhg O’Dwyer2 
1. Department of Otolaryngology, Head and Neck Surgery, University Hospital Limerick 
2. Department of Otolaryngology, Head and Neck Surgery, Mater Misericordiae University 
Hospital, Dublin  
  
 
5.3.1 Background to the publication 
This article once again came about due to the ongoing enthusiasm for the use of an 
absolute white cell count over 4x109/L as a diagnostic screening tool. Biggs et al carried 
out a larger retrospective review of 726 patients that had Monospot testing(Biggs et al. 
2013). They found that a lymphocyte count of ≤4 x 109/L was associated with negative 
Monospot result in 99% of patients. They concluded that this parameter was a highly reliable 
negative predictor of EBV-related IM and suggested limiting routine Monospot and/or 
serological testing to suspected cases of EBV-related IM in patients with a lymphocyte count 
>4 x 109⁄L. These results again differed substantially from the findings that we had published, 
and therefore we wrote a letter to the editor warn of the potential pitfalls of such an approach.   
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5.3.2 Letter to the Editor  
 
“Dear Editor, 
We read the recent article by Biggs et al (Biggs et al. 2013) on the use of the absolute 
lymphocyte count in the diagnosis of infectious mononucleosis. We carried out a 
similar study on the use of the lymphocyte to white cell ratio (Lennon et al. 2010), and 
later reanalyzed our data using an absolute lymphocyte count above 4 (Lennon et al. 
2013a), in response to an earlier study carried out by Biggs et al (Biggs 2011). We 
would like to highlight the divergence in results between our study and the current study 
by Biggs et al. The authors analyzed 50 patients with positive monospot tests, and found 
a negative predictive value of 99%, specificity of 94%, and sensitivity of 84%. Our 
cohort had 500 positive monospot results, and we found a negative predictive value of 
71.7%, a specificity of 96.8%, and sensitivity of 61.8%. Our article demonstrated that 
a much larger number of patients had positive monospots with a lymphocyte count of 
<4 (191 cases), suggesting that the use of the lymphocyte count is associated with a 
high rate of false-negative results. 
 
As with the paper by Wolf et al (Wolf et al. 2007) previously, we recommend the 
continued use of the Hoagland criteria (Hoagland 1975) for diagnosis of infectious 
mononucleosis, as the modest saving incurred with the abandonment of the monospot 
test may lead to the provision of misinformation on recovery, including the avoidance 
of contact sports, and potentially far greater costs to both the patient and the medical 
institution involved.” 
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5.4 No new evidence to support the routine use of steroids in 
the treatment of infectious mononucleosis. 
 
Paul Lennon1, 2, Michael Crotty3, John E. Fenton1, 2 
1. Department of Otolaryngology, Head and Neck Surgery, University Hospital Limerick, 
Dooradoyle, Limerick, Ireland 
2. Graduate Entry Medical School, University of Limerick, Ireland  
3. General Practice, Synergy Medical Clinic, Sherwood Park, Edmonton, Alberta, Canada 
 
5.4.1 Background to the publication 
Evidence-Based Medicine is a review journal of the British Medical Journal. Its stated 
goal is to systematically search “a wide range of international medical journals 
applying strict criteria for the validity of research. Content is critically appraised then 
the most clinically relevant articles are summarised into an expert commentary 
focusing on the papers clinical applicability (Evidence-Based Medicine  2016)”. The 
Cochrane review suggests that published systematic reviews be regularly updated 
(Cochrane Review updates  2016).  As steroid use in IM was a component of the 
review we had carried out published by the BMJ, we were invited to comment on the 
most recent update of the systematic review of steroid use in IM by Candy et al 
(Candy and Hotopf 2006). 
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5.4.2 Invited Review 
 
5.4.2.1 Context  
Infectious mononucleosis is a non-genetic syndrome, defined by the classic triad of 
fever, pharyngitis and cervical lymphadenopathy, where lymphocytosis is also present. 
Over 90% of cases are caused by the Epstein Barr virus, which results in a subclinical 
infection in childhood and to which 95% of the population have seroconverted by 
adolescent (Lennon et al. 2015). Infection after this time will result in IM, which has 
been shown to be a more severe illness than simple bacterial tonsillitis(Lennon et al. 
2013b). Therefore, attempts are ongoing to expand the treatment armamentarium 
(Lennon et al. 2014a). Some early reports supported the use of corticosteroids in the 
treatment of IM, but other trials showed these effects to be short lived. A Cochrane 
review was undertaken in 2006, which concluded that there was insufficient evidence 
and the trials were too few, heterogeneous, and of poor quality to recommend steroid 
treatment for symptom control in glandular fever (Candy and Hotopf 2006). This 
systematic review, carried out by different authors, is an update on the initial study and 
subsequent updates in 2009 and 2011. 
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5.4.2.2 Methods  
This was a review of randomised controlled trials examining the effects of steroids in 
IM. The patients could be of any age with confirmed IM by serology or monospot test. 
The intervention was steroids of any dose, duration or route of administration. The 
comparators were either placebo, standard of care or another agent. The outcomes 
included improvement in health and duration of symptoms, but also adverse events due 
to steroid use. The authors used the standard methodological procedures set out by the 
Cochrane review. As this is an update, the authors searched for new studies carried out 
between 2011 and 2015. The results depended on the individual study with odds ratio 
(OR), 95% confidence interval (CI) or mean difference (MD) reported. 
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5.4.2.3 Findings. 
The authors reported no new studies that met the inclusion criteria for this update. One 
hundred and eighty-six search results were found to be irrelevant. There were no studies 
found, ongoing or completed, in several trial registries. In fact, no new studies have 
been added in any of the three updates that have been undertaken thus far. The original 
review included 7 RCTs with a total of 362 patients. The quality of the evidence was 
generally found to be poor and the heterogeneity between trials prevented a combined 
analysis. For instance, from the intervention perspective there was a wide range of dose 
regimes, ranging from a single dose to a 12-day course. On the comparator side, 4 
studies had a placebo arm, but others compared steroids to aspirin or combined steroids 
with an antiviral. The authors found evidence from two trials that steroids were 
effective in reducing the symptoms of sore throat initially but not after 12 hours of 
treatment. Evidence on other symptoms was limited and a number of adverse events, 
including peritonsillar abscess, empyema and the development of diabetes mellitus 
were reported in patients treated with steroids. The authors concluded that there is not 
enough evidence to the efficacy of corticosteroid treatment for symptom control in 
people with otherwise uncomplicated glandular fever.   
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5.4.2.4 Commentary 
The Cochrane website suggests two yearly updates of its studies in order to maintain a 
contemporary status(Cochrane Review updates  2016). This is the third update of the 
original systematic review and meta-analysis carried out by Candy et al in 2006. There 
were no new studies found in the interim and the level of evidence remains poor. The 
number of studies, and number of patients in each, resulted in many of the analyses 
having wide confidence intervals with little assurance to the real effect of steroids in 
IM. Anecdotally there has been an increase in the use of steroids to treat IM in the 
emergency room setting (Lennon et al. 2014a). This may have resulted from a more 
recent Cochrane review on a similar topic, which concluded that corticosteroids 
increased the likelihood of both resolution and improvement of pain in participants with 
sore throat (Hayward et al. 2012). Although this review excluded studies with IM, many 
patients are likely to receive steroids prior to a diagnosis of IM being made in an 
emergency room setting. This review again reiterated that there is no good data for the 
routine use of steroids and highlights a number of possible adverse events that may be 
associated with their use. 
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5.4.2.5 Implications for practice 
Consideration for the use of steroids in IM should be reserved for patients with 
impending airway compromise. However their routine use, without a clear evidence 
base, remains widespread (Thompson et al. 2005). Clinical equipoise remains 
important and additional studies, with greater numbers of patients and improved study 
designs, are required prior to a comprehensive recommendation. There is currently 
insufficient evidence to recommend corticosteroid treatment for symptom control for 
people with otherwise uncomplicated IM 
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